"Showcasing Global Export Products,
Expanding Overseas Partnerships"

Samchundang Pharmaceutical announced on October 2 that it will participate in the global pharmaceutical industry exhibition 'CPHI 2026,' to be held in Milan, Italy, from June 6 to 8.


CPHI is a global exhibition that brings together companies from across the pharmaceutical industry, covering everything from active pharmaceutical ingredients (APIs) to finished drugs, biopharmaceuticals, contract development and manufacturing (CDMO), and drug delivery technologies. Each year, more than 2,500 companies participate in the event.


Rendering of the Samchundang Pharmaceutical booth to be installed at the global pharmaceutical industry exhibition "CPHI 2026," held in Milan, Italy, from the 6th to the 8th. Samchundang Pharmaceutical

Rendering of the Samchundang Pharmaceutical booth to be installed at the global pharmaceutical industry exhibition "CPHI 2026," held in Milan, Italy, from the 6th to the 8th. Samchundang Pharmaceutical

View original image

This year, Samchundang Pharmaceutical will set up its own independent booth for the first time. From 2011 to last year, the company participated in the joint Korean Pavilion hosted by the Korea Trade-Investment Promotion Agency (KOTRA) and the Korea Pharmaceutical Traders Association.


At the exhibition, the company will showcase Eylea biosimilar SCD411 (marketed domestically as Bizenfree), a treatment for macular degeneration sold in Korea, Canada, and major European countries, as well as eye drops for the treatment of glaucoma, ocular hypertension, and allergic conjunctivitis currently being exported to Europe and the United States.


Samchundang Pharmaceutical will also introduce its pipeline of follow-on biosimilars for retinal diseases based on its experience in the development, approval, and commercialization of SCD411. This includes a high-dose version of Eylea.


The company is also developing an oral insulin, oral GLP-1, long-acting injectables, and immuno-oncology biosimilars, for which it plans to hold one-on-one meetings with global pharmaceutical companies regarding technology licensing and joint development opportunities.


Samchundang Pharmaceutical began exporting single-use eye drops to Europe in 2022, starting with Travoprost 0.004% eye drops. Since 2025, the company has been supplying SCD411 to overseas markets including Canada and Europe.



A Samchundang Pharmaceutical official stated, "Building on our production capabilities that meet the manufacturing and quality control standards of regulatory authorities in Europe and the United States, we will expand our collaboration with global partners and continue to tap into overseas markets."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing